Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > SP

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Mar 23, 2023 8:07pm

198 Views

Post# 35357669

RE:RE:RE:SP

That story ignores some basic facts.

All those trials were as monotherapy, assuming direct lysis of cancer cells is the right mechanism for pela success.

What is the company doing now?

NOT THAT APPROACH.

It is now being tested with really surprising and remarkable success as an I/O agent in combination therapies.

Ionc's comments would be fair and reasonable if we were still doing monotherapy.

But since we are not doing that, it is hard to take the recent comments seriously.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing